Approval · Notice of Compliance 6301 · 2005
GLUCONORM: Notice of Compliance 6301
Issued March 2, 2005
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 6301
- Date
- March 2, 2005
- Company
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: use of repaglinide in combination with rosiglitazone
- Therapeutic class
- Oral antidiabetic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| GLUCONORM | Not yet assigned | — |
Medicinal ingredients
- REPAGLINIDE 0.5 MG per TAB
- REPAGLINIDE 1 MG per TAB
- REPAGLINIDE 2 MG per TAB